Journal article
Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics
TE Hartnett, AJ Oconnor, K Ladewig
Expert Opinion on Drug Delivery | TAYLOR & FRANCIS LTD | Published : 2015
Abstract
Introduction: Many macromolecular therapeutics designed to treat posterior segment eye diseases (PSEDs) are administered through frequent ocular injection, which can further deteriorate eye health. Due to the high frequency of injection and the high cost of the therapeutics, there is a need to develop new ways in which to deliver these therapeutics: ways which are both safer and more cost effective.Areas covered: Using the most common PSED, age-related macular degeneration, as an example of a debilitating ocular disease, this review examines the key barriers limiting the delivery of macromolecular therapeutics to the posterior segment of the eye and defines the key requirements placed on par..
View full abstractGrants
Funding Acknowledgements
The review was funded by the Australian Research Council. The authors declare no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.